AnaptysBio Prepares for a Potential Gear Shift
There wasn't much financial activity to report during the second quarter of 2019, but it was still a rough one for AnaptysBio (NASDAQ: ANAB) and its lead candidate, etokimab. Positive midstage clinical trial results that the company announced in early June didn't ignite any fireworks for the stock, but early results from a similar new drug candidate that Regeneron (NASDAQ: REGN) is developing took a heavy toll.
Data source: AnaptysBio.
In June, AnaptysBio released results from a 25-patient study with etokimab and patients with severe asthma. Two days after beginning the trial, patients treated with a single infusion of etokimab increased their forced expiration volume scores by 12%, compared with a 4% gain over baseline reported from the placebo group. At Day 64, the placebo group was still at 4% while the etokimab group's improvement relative to baseline rose to 15%.
Source Fool.com
